Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Experimental, Transplantation, Homologous, Islets of Langerhans Transplantation
Interventions
hOKT3gamma1 (Ala-ala)
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Terminated Phase 2 Interventional Results available

PsA Treatment With hOKT3γ1 (Ala-Ala)

NCT00239720
Conditions
Arthritis, Psoriatic
Interventions
hOKT3gamma1(Ala-Ala), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Conditions
Diabetes Mellitus, Type 1
Interventions
hOKT3gamma1(Ala-Ala)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Completed Phase 2 Interventional Results available

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

NCT00378508
Conditions
Type 1 Diabetes Mellitus
Interventions
mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 30 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 1 more